sharp
increas
number
case
rapidli
argentina
brazil
becam
countri
highest
number
death
due
microbiolog
confirm
pandem
influenza
consist
particular
situat
health
system
metropolitan
area
bueno
air
began
show
evid
collaps
use
ventil
increas
critic
achiev
extrem
unusu
level
quarter
avail
icu
bed
occupi
young
previous
healthi
patient
ard
associ
sever
bilater
pneumonia
due
swine
flu
need
mechan
ventil
time
write
chapter
end
winter
southern
hemispher
evid
pandem
influenza
highli
preval
south
america
septemb
world
health
organ
director
gener
margaret
chan
estim
peopl
dens
popul
countri
risk
infect
pandem
influenza
dr
thoma
frieden
head
us
center
diseas
control
prevent
predict
peopl
may
potenti
infect
new
york
citi
spring
figur
difficult
extrapol
global
confirm
epidemiolog
studi
look
popul
risk
differ
world
area
lack
huge
number
sever
ill
patient
ard
due
primari
influenza
pneumonia
extrem
unusu
complic
observ
southern
cone
suggest
estim
could
realist
calcul
populationcorrect
mortal
rate
estim
made
new
zealand
infer
end
winter
southern
hemispher
popul
argentina
could
infect
novel
agent
influenza
complic
season
influenza
occur
frequent
patient
older
year
old
chronic
disord
includ
cardiac
pulmonari
diseas
diabet
mellitu
hemoglobinopathi
renal
dysfunct
immunosuppress
pregnant
women
second
third
trimest
particularli
pandem
higher
risk
complic
especi
primari
influenza
pneumonia
higher
hospit
rate
pneumonia
signific
complic
influenza
present
pneumonia
includ
primari
influenza
viral
pneumonia
secondari
bacteri
pneumonia
mix
viral
bacteri
pneumonia
primari
influenza
viral
pneumonia
may
least
common
pneumon
complic
also
sever
present
acut
influenza
resolv
instead
progress
relentlessli
persist
fever
dyspnea
eventu
cyanosi
sputum
product
gener
scanti
sputum
contain
blood
physic
sign
may
evid
earli
ill
advanc
case
diffus
rale
may
note
chest
xray
find
consist
diffus
interstiti
infiltr
andor
ard
may
present
fig
viral
cultur
respiratori
specimen
especi
yearold
obes
male
arteri
hypertens
secondari
cush
diseas
hypophys
adenoma
develop
bilater
pneumonia
die
respiratori
failur
secondari
acut
respiratori
distress
syndrom
ard
day
mechan
ventil
multipl
organ
failur
includ
renal
hemodynam
compromis
requir
high
dose
vasopressor
diseas
began
influenzalik
ill
day
admiss
influenza
confirm
rtpcr
perform
pharyng
swab
postmortem
microscop
histopatholog
find
lung
includ
extens
alveolar
edema
small
arrow
replac
effect
alveolar
space
hyalin
membran
develop
big
arrow
alveolar
cellular
infiltr
bacteri
superinfect
arrowhead
also
observ
diffus
alveolar
damag
pattern
panel
also
mild
evid
fibroprolif
stage
microthrombi
gray
arrow
small
area
well
preserv
pulmonari
parenchyma
blue
arrow
hemorrhag
infarct
panel
b
suprarren
hyperplasia
acut
tubular
necrosi
found
sampl
taken
earli
ill
yield
high
titer
viru
fatal
case
primari
viral
pneumonia
histopatholog
examin
reveal
mark
inflammatori
reaction
alveolar
septa
edema
infiltr
lymphocyt
macrophag
occasion
plasma
cell
variabl
number
neutrophil
fig
fibrin
thrombi
alveolar
capillari
along
necrosi
hemorrhag
also
note
hyalin
membran
found
line
alveoli
alveolar
duct
primari
influenza
viral
pneumonia
predilect
individu
cardiac
diseas
particularli
mitral
stenosi
also
report
otherwisehealthi
young
adult
well
older
individu
chronic
pulmonari
disord
secondari
bacteri
pneumonia
follow
acut
influenza
case
typic
improv
patient
condit
day
follow
reappear
fever
along
clinic
sign
symptom
pneumonia
includ
cough
purul
sputum
physic
xray
sign
consolid
common
bacteri
pathogen
set
streptococcu
pneumonia
staphylococcu
aureu
haemophilu
influenza
usual
nasopharynx
colon
secondari
bacteri
pneumonia
occur
frequent
highrisk
individu
cm
luna
r
valentini
rizzo
chronic
pulmonari
cardiac
diseas
elderli
individu
patient
secondari
bacteri
pneumonia
often
respond
antibiot
therapi
institut
promptli
risk
factor
acquir
sever
primari
influenza
pneumonia
includ
age
particularli
young
children
comorbid
seri
observ
particular
preval
overweight
individu
group
patient
obes
previous
mention
among
risk
factor
complic
patient
influenza
overweight
associ
chronic
increas
proinflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
experiment
model
influenza
smith
et
al
describ
higher
mortal
rate
overweight
patient
lean
control
relat
minim
express
interferon
ifn
delay
express
proinflammatori
cytokin
may
lead
increas
morbid
mortal
viral
infect
contrast
happen
usual
annual
season
influenza
outbreak
outbreak
pandem
influenza
young
adult
die
one
quarter
one
half
death
around
world
happen
patient
previous
good
health
without
specif
risk
factor
one
earlier
case
report
public
begin
pandem
mexico
author
observ
death
case
sever
pneumonia
involv
patient
age
year
compar
averag
rate
respect
age
group
refer
period
featur
epidem
similar
past
influenza
pandem
circul
new
influenza
viru
associ
offseason
wave
diseas
affect
younger
popul
set
diseas
high
mortal
avail
control
human
clinic
data
guid
clinician
patient
present
sever
diseas
number
combin
strategi
consid
therapi
includ
pharmacolog
strategi
antivir
treatment
nonpharmacolog
strategi
standard
optim
ventil
fluid
manag
especi
ard
manag
complic
necessarili
given
empir
diagnost
confirm
use
real
time
reversetranscriptas
polymeras
chain
reaction
rtpcr
take
sever
hour
day
p
plat
eetp
c
stat
pulm
drive
pr
eitp
v
v
patient
ard
patient
ventilatori
support
follow
concept
protect
ventil
tidal
volum
v
mlkg
predict
bodi
weight
ard
usual
sever
pao
fio
posit
endexpiratori
pressur
peep
high
optim
accord
mechan
basi
experi
initi
select
peep
accord
method
use
express
trial
peep
adjust
base
airway
pressur
kept
high
possibl
without
increas
maxim
inspiratori
plateau
pressur
cmh
sever
respiratori
failur
also
set
peep
accord
transpulmonari
pressur
use
esophagealpressur
measur
secondari
also
primari
ard
lung
suffer
substanti
effect
chest
wall
elast
may
effect
compress
high
pleural
pressur
alveoli
collaps
end
expir
even
though
moder
high
peep
level
appli
therefor
peep
set
level
necessari
obtain
posit
endexpiratori
transpulmonarypressur
improv
oxygen
endinspiratori
transpulmonarypresur
less
cmh
minim
stressinduc
ventil
lung
injuri
pulmonari
drive
pressur
endinspiratori
transpulmonari
pressur
less
endexpiratori
transpulmonari
pressur
e
cmh
avoid
straininduc
ventil
lung
injuri
fig
use
premis
mean
peep
appli
patient
sever
influenza
ard
cmh
interestingli
contrast
etiolog
ard
primari
influenza
pneumonia
high
peep
level
necessari
mani
day
group
patient
variat
ga
exchang
respiratori
system
mechan
onset
mechan
ventil
group
mechan
ventil
ard
patient
pneumonia
observ
one
icu
variabl
improv
day
day
mechan
ventil
howev
major
patient
pao
fio
ratio
remain
low
mani
day
induc
us
maintain
high
level
peep
cstat
static
lung
complianc
peep
posit
endexpiratori
pressur
manag
one
us
rv
cemic
medic
center
mean
peep
day
mechan
ventil
cmh
begin
outbreak
decreas
peep
level
day
mechan
ventil
base
improv
oxygen
level
howev
produc
dramat
worsen
pao
fio
ratio
observ
decid
patient
sever
ard
high
peep
level
maintain
least
two
week
regardless
oxygen
level
fig
patient
sever
influenza
pneumonia
respond
recruit
maneuv
recruit
maneuv
pressur
control
ventil
pcv
peep
cmh
inspiratori
pressur
cmh
peak
pressur
cmh
perform
patient
pao
fio
mmhg
mani
patient
young
healthi
good
cardiac
perform
toler
high
ventilatori
pressur
recruit
maneuv
adequ
intravascular
volum
replet
sever
trial
demonstr
surviv
benefit
ard
patient
manag
prone
posit
howev
trial
select
sever
patient
mani
patient
sever
ard
pao
fio
mmhg
despit
peep
optim
recruit
maneuv
set
prone
ventil
use
pao
fio
reach
mmhg
recruit
maneuv
appli
prone
posit
prone
ventil
use
patient
ard
patient
sever
ard
associ
improv
oxygen
reduc
distend
pressur
suggest
use
adjunct
therapi
plateau
pressur
higher
cmh
despit
v
mlkg
predict
weight
sever
hypercapn
acidosi
refractori
hypoxemia
defin
pao
fio
ratio
mmhg
optim
peep
recruit
maneuv
prone
posit
recruit
maneuv
prone
ventilatori
posit
adjunct
therapi
develop
reduc
stress
mechan
ventil
alreadi
damag
lung
includ
nitric
oxid
extracorpor
membran
oxygen
ecmo
arteri
venou
carbon
dioxid
remov
highfrequ
oscillatori
ventil
liquid
ventil
prefer
use
avail
easi
implement
observ
better
improv
oxygen
combin
therapi
prone
ventil
previous
describ
noninvas
posit
pressur
ventil
nppv
nppv
use
respiratori
failur
due
viral
pneumonia
even
case
high
transmiss
risk
like
epidem
sever
acut
respiratori
syndrom
sar
hong
kong
one
studi
efficaci
sar
pneumonia
mild
acut
lung
injuri
ali
high
case
healthwork
infect
observ
howev
applic
nppv
patient
influenza
well
evalu
indic
impend
respiratori
failur
mild
case
patient
chronic
obstruct
pulmonari
diseas
copd
chronic
respiratori
restrict
nppv
could
use
support
respiratori
system
appli
healthcar
facil
staff
adequ
train
strict
enforc
person
protect
measur
use
expiratori
viral
bacteri
filter
necessari
provid
safer
ventil
patient
influenza
recov
without
antivir
therapi
antivir
indic
prevent
rapid
spread
diseas
specif
popul
prevent
pneumonia
syndrom
suscept
patient
treat
patient
influenza
pneumonia
critic
ill
influenza
patient
antivir
treatment
option
limit
parenter
drug
avail
drug
prove
effect
lifethreaten
diseas
occur
current
four
antivir
drug
avail
treatment
influenza
amantadin
rimantadin
use
treatment
influenza
due
resist
oseltamivir
avail
oral
administr
zanamivir
avail
inhal
agent
two
latter
drug
sialic
acid
analog
inhibit
viral
neuraminidas
competit
bind
activ
enzym
site
influenza
b
virus
neuraminidas
critic
viral
releas
infect
cell
replic
earlier
administr
agent
shorter
durat
fever
greater
benefit
drug
intervent
oseltamivir
also
shown
reduc
lower
respiratori
tract
complic
bronchiti
pneumonia
prospect
case
control
studi
multivari
analysi
suggest
treatment
oseltamivir
decreas
likelihood
death
odd
ratio
confid
interv
p
immunosuppress
patient
leukemia
organ
transplant
hematopoiet
stem
cell
transplant
higher
rate
viral
pneumonia
higher
attribut
mortal
viral
shed
also
prolong
patient
averag
day
associ
develop
resist
standard
dose
durat
antivir
may
adequ
popul
reason
author
advoc
higher
dose
oseltamivir
mg
daili
patient
pandem
therapeut
strategi
propos
argentinean
health
author
mechan
ventil
patient
presumpt
primari
influenza
pneumonia
use
oseltamivir
dose
mg
daili
extend
period
time
typic
patient
wean
mechan
ventil
frequent
report
advers
effect
seen
oseltamivir
nausea
vomit
lead
medic
interrupt
small
number
case
neuropsychiatr
disord
seizur
confus
hyperexcit
nervou
system
sever
skin
reaction
eg
toxic
epiderm
necrolysi
sever
advers
event
observ
case
pandem
unusu
event
relat
singl
nucleotid
polymorph
gene
locat
near
enzymat
activ
site
human
cytosol
sialidas
homolog
viru
neuraminidas
target
oseltamivir
polymorph
found
occur
asian
popul
high
frequenc
bacteri
coinfect
antibiot
administr
recommend
patient
pandem
influenza
infect
requir
admiss
critic
care
unit
immunocompet
patient
without
recent
antibiot
exposur
combin
therapi
betalactam
plu
macrolid
respiratori
fluorquinolon
recommend
corticosteroid
may
use
treat
airflow
obstruct
due
asthma
copd
maintain
immunosuppress
transplant
patient
adren
dysfunct
suspect
refractori
vasodilatori
shock
corticosteroid
indic
ali
prolong
highdos
corticosteroid
therapi
result
seriou
advers
event
includ
opportunist
infect
patient
pulmonari
infect
corticosteroid
effect
one
seri
mortal
recipi
corticosteroid
compar
patient
receiv
corticosteroid
one
except
cryptogen
organ
pneumonia
cop
describ
complic
addit
primari
viral
pneumonia
viral
bacteri
coinfect
secondari
bacteri
pneumonia
frequent
coinfect
pneumonia
aureu
mycoplasma
pnemonia
detect
report
seri
argentina
coinfect
occur
sever
day
influenza
infect
occur
frequent
elderli
patient
chronic
pulmonari
diseas
observ
one
seri
hospit
patient
communityacquir
pneumonia
dual
infect
respiratori
viru
bacteri
pathogen
influenza
common
viral
agent
propos
theori
high
incid
superimpos
bacteri
infect
influenza
pneumonia
emphas
synergist
effect
viral
bacteri
pathogen
produc
lung
injuri
studi
suggest
influenza
viru
directli
damag
respiratori
epithelium
allow
free
access
invad
bacteria
also
demonstr
lifethreaten
respiratori
failur
influenza
vi
staphylococcu
streptococcu
strain
may
increas
viral
replic
pathogen
contribut
influenza
viral
pneumonia
pulmonari
embol
recogn
common
complic
sever
influenza
ard
howev
seri
patient
pandem
influenza
infect
ard
tertiarycar
icu
michigan
five
pulmonari
emboli
influenza
infect
associ
procoagul
chang
patholog
fibrin
deposit
also
occur
vasculatur
ard
pulmonari
arteri
thrombi
found
impli
anatom
mechan
occurr
increas
pulmonari
vascular
resist
ard
remain
unknown
whether
case
secondari
sever
risk
factor
bedridden
sever
ill
patient
whether
direct
consequ
particular
risk
influenza
patient
meanwhil
clinician
period
search
thrombosi
necessari
use
chest
multislic
spiral
comput
tomographi
ct
confirm
pulmonari
embol
influenza
viru
replic
alveoli
tissu
beyond
respiratori
tract
histopatholog
analys
reveal
viru
detect
liver
spleen
kidney
brain
anim
inocul
influenza
viru
day
inocul
howev
myocard
pericard
describ
associ
influenza
infect
suggest
influenzaassoci
myocard
take
two
form
immedi
associ
fulmin
diseas
delay
occur
late
convalesc
renal
failur
describ
number
influenza
patient
usual
consequ
shock
multiorgan
dysfunct
recommend
adequ
fluid
replac
patient
sever
ard
fluid
infus
restrict
diuret
use
avoid
prevent
progress
renal
dysfunct
use
strategi
patient
posit
fluid
balanc
th
day
ml
hemodialysi
necessari
patient
occasion
rhabdomyolysi
may
facilit
develop
renal
failur
fact
high
level
serum
creatin
phosphokinas
describ
report
infect
condit
occasion
associ
influenza
character
progress
respiratori
failur
week
influenza
symptom
chest
computer
axial
tomographi
demonstr
multipl
bilater
patchi
alveolar
opac
identifi
complic
must
treat
high
dose
corticosteroid
ho
et
al
perform
studi
defin
prognost
factor
fatal
adult
influenza
pneumonia
univari
analysi
demonstr
compar
survivor
septic
shock
respiratori
rate
breath
per
min
arteri
ph
pao
fio
ratio
mmhg
creatinin
valu
mgdl
pneumonia
sever
index
psi
iv
v
apach
ii
score
associ
decreas
surviv
adjust
made
septic
shock
respiratori
rate
arteri
ph
creatinin
psi
cox
proport
hazard
model
multivari
analysi
demonstr
pao
fio
ratio
mmhg
p
apach
ii
score
p
remain
associ
death
anoth
studi
develop
ard
histori
immunosuppress
independ
risk
factor
hospit
mortal
critic
ill
patient
confirm
influenza
viru
infect
emerg
antigen
novel
influenza
viru
littl
antibodi
present
commun
result
extens
outbreak
absenc
antibodi
worldwid
reason
pandem
independ
antigen
new
viru
question
regard
potenti
effect
vaccin
season
influenza
aris
one
interim
analysi
pandem
australia
author
found
evid
signific
protect
season
vaccin
pandem
influenza
viru
infect
age
group
new
vaccin
develop
concern
base
experi
flu
season
swine
flu
outbreak
fort
dix
new
jersey
led
feder
govern
expedit
vaccin
product
million
peopl
vaccin
time
syndrom
identifi
side
effect
howev
pandem
realiti
consid
benefit
vaccin
far
outweigh
risk
pandem
provid
dramat
evid
impact
influenza
morbid
mortal
caus
first
influenza
pandem
st
centuri
character
unusu
increas
number
case
primari
viral
sever
communityacquir
pneumonia
requir
mechan
ventil
substanti
interestingli
higher
incid
sever
case
appear
younger
age
group
usual
involv
annual
season
flu
outbreak
percentag
popul
acquir
influenza
pandem
yet
estim
certainli
much
higher
season
influenza
higher
incid
may
explain
high
number
case
sever
primari
pneumonia
observ
southern
cone
appar
less
aggress
natur
infect
younger
popul
affect
may
explain
estim
mortal
rate
lower
observ
season
influenza
complic
mortal
season
flu
frequent
among
patient
year
old
chronic
disord
includ
cardiac
pulmonari
diseas
diabet
mellitu
hemoglobinopathi
renal
dysfunct
immunosuppress
also
usual
associ
older
age
improv
standard
optim
icu
care
patient
influenza
includ
young
immunocompet
patient
without
comorbid
lead
lower
mortal
previous
observ
influenza
pneumonia
mechan
support
requir
pandem
influenza
result
tremend
pressur
critic
care
system
unexpect
rapid
influx
larg
number
patient
emerg
room
critic
care
servic
highlight
shortag
critic
care
capac
also
inadequ
suppli
critic
care
resourc
extrem
sever
ard
patient
necessit
chang
usual
approach
manag
patient
improv
success
rate
health
system
must
prepar
realloc
resourc
respons
demand
therefor
earli
recognit
probabl
viral
pneumonia
crucial
order
implement
earli
infectioncontrol
strategi
reduc
transmiss
healthcar
worker
high
risk
exposur
pathogen
